SCHEMBL8798263

SCHEMBL8798263

Cc1ccc(OC(C)C)c([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.58
TSHR P16473 2/20 0.56
CYP3A4 P08684 1/20 0.56
ALDH1A1 P00352 8/20 0.50
LMNA P02545 4/20 0.50
MAPT P10636 2/20 0.50
S1PR4 O95977 1/20 0.50
MAPK1 P28482 1/20 0.50
KDM4E B2RXH2 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
AGTR1 P30556 1/20 0.46
XDH P47989 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1340227 0.86 TSHR (0.56) PDK1TSHRCYP3A4ALDH1A1LMNA
SCHEMBL14553750 0.85 TSHR (0.59) PDK1TSHRCYP3A4ALDH1A1LMNA
SCHEMBL22897826 0.84 ALDH1A1 (0.53) TSHRCYP3A4ALDH1A1LMNAMAPT
SCHEMBL29559314 0.84 ALDH1A1 (0.53) TSHRCYP3A4ALDH1A1LMNAMAPT
SCHEMBL6809251 0.83 PDK1 (0.58) PDK1TSHRALDH1A1LMNAMAPT
SCHEMBL29749825 0.83 PDK1 (0.58) PDK1TSHRALDH1A1LMNAMAPT
SCHEMBL9687621 0.82 TSHR (0.64) TSHRCYP3A4ALDH1A1LMNAMAPT
SCHEMBL14136388 0.81 PDK1 (0.57) PDK1TSHRCYP3A4ALDH1A1LMNA
SCHEMBL19175613 0.81 PDK1 (0.61) PDK1TSHRALDH1A1LMNAMAPT
SCHEMBL16958967 0.81 PDK1 (0.57) PDK1TSHRCYP3A4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0365328-B1 Pyridine derivatives ZENECA LTD (GB) 1996-04-03 EP claimed
US-5053415-A Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-10-01 US claimed
EP-0365328-A2 Pyridine derivatives ZENECA LIMITED (GB) 1990-04-25 EP claimed
CN-118993987-A Preparation method of 5-methyl-2-isopropoxy-4- (4-piperidine) -aniline dihydrochloride monohydrate 广州科锐特生物科技有限公司 2024-11-22 CN disclosed
CN-115215788-B Preparation method of ceritinib key intermediate 苏州凯瑞医药科技有限公司 2023-09-22 CN disclosed
CN-115215788-A Preparation method of ceritinib key intermediate 苏州凯瑞医药科技有限公司 2022-10-21 CN disclosed
US-20180057457-A1 Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof NOVARTIS AG (CH) 2018-03-01 US disclosed
WO-2016199020-A1 PROCESS FOR PREPARATION OF CERITINIB DR. REDDY'S LABORATORIES LIMITED (IN) 2016-12-15 WO disclosed
WO-2016199020-A1 PROCESS FOR PREPARATION OF CERITINIB DR. REDDY'S LABORATORIES LIMITED (IN) 2016-12-15 WO disclosed
CN-106146387-A The preparation method of ALK inhibitor 湖北生物医药产业技术研究院有限公司 2016-11-23 CN disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
CN-104803908-A Hydrate of 2-isopropoxy-5-methyl-4-(4-piperidyl) aniline dihydrochloride as well as preparation method and application of hydrate 2Y CHEM LTD 2015-07-29 CN disclosed
CN-104447515-A New intermediates for preparing ceritinib and preparation method of intermediate 2Y CHEM LTD 2015-03-25 CN disclosed
EP-0482771-B1 Heterocyclic acids ZENECA LTD (GB) 1997-06-18 EP disclosed
EP-0365328-B1 Pyridine derivatives ZENECA LTD (GB) 1996-04-03 EP disclosed
US-5410064-A Thromboxane A2 antagonists and inhibitors of thromboxane A2 synthase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-04-25 US disclosed
US-5219874-A Heterocyclic acids IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-15 US disclosed
EP-0482771-A2 Heterocyclic acids ZENECA LIMITED (GB) 1992-04-29 EP disclosed
US-5053415-A Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-10-01 US disclosed
EP-0365328-A2 Pyridine derivatives ZENECA LIMITED (GB) 1990-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057457-A1 Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof PDXK, DCK, DPYD PDK1 482/4885TSHR 1767/4885CYP3A4 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.